Drug intelligence / Profile preview

etybenzatropine

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intravenous, Intramuscular

Overview

Etybenzatropine is an anticholinergic drug structurally related to benztropine. Like benztropine, it is presumed to act primarily as a muscarinic acetylcholine receptor antagonist in the central nervous system, reducing the effects of acetylcholine and thereby helping to restore the balance between dopamine and acetylcholine. This mechanism is useful in treating symptoms of Parkinson's disease and drug-induced extrapyramidal symptoms. Etybenzatropine may also have some antihistaminic properties due to its structural similarity with other tropane derivatives.

Targets

M1 (Muscarinic acetylcholine receptor M1)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on etybenzatropine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on etybenzatropine.

Explore the full profile